Radium-223 international early access program: results from the Spanish subset.
Future Oncol
; 14(1): 41-50, 2018 Jan.
Article
em En
| MEDLINE
| ID: mdl-29232987
ABSTRACT
AIM:
To report results from the Spanish subset included in the radium-223 international early access program (iEAP). PATIENTS &METHODS:
Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles.RESULTS:
The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with ≥50% confirmed declines in prostate-specific antigen was 9%. The median overall survival was 14 months. Grade 3 or 4 treatment emergent adverse events (TEAEs) occurred in 34% of patients (serious TEAEs 28%, TEAEs leading to discontinuation 27%).CONCLUSION:
Outcomes of the Spanish subset are consistent with the iEAP. Radium-223 was generally well tolerated with no safety concerns.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos
/
Neoplasias Ósseas
/
Rádio (Elemento)
/
Neoplasias de Próstata Resistentes à Castração
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article